In patients with congestive heart failure, the release of atrial natriuretic peptide (ANP) 
Atrial natriuretic peptide (ANP) released from atrial myocytes is a vasoactive peptide that primarily acts in regulating urine flow and sodium excretion, t-5 In normal subjects, increased atrial pressure causing distension and stimulation of atrial myocytes initiates ANP release. 6-7 Studies of patients with congestive heart failure (CHF) indicated an elevated resting concentration of plasma ANP but, when compared with normal subjects, the amount of ANP released from atria in response to graded increases in right atrial pressure was reduced, s'9 Further, patients with valvular heart disease and dilated cardiomyopathy released only half the amount of ANP in response to increased atrial pressure as did CHF patients. 9 In experimental studies, atrial tissues of spontaneous hypertensive rats t~ and Syrian hamsters ~ with cardiomyopathy showed depletion of ANP. It has been suggested that the secretory mechanism of ANP in patients with CHF is different from normal subjects. 9 To expand upon these findings, this study was undertaken to measure and evaluate ANP, sympathetic and haemodynamic responses to an acute increase in atrial pressure in patients with refractory cardiomyopathy.
Methods
Seventeen patients scheduled for orthotopic cardiac transplantation were randomly divided into two treatment groups. Institutional Review Board approval and informed consent were obtained. All patients had terminal heart disease with ejection fractions <0.27. The inotropic and vasodilator medications, dobutamine (most patients), amrinone, and nitroglycerin, were continued until the time of induction of anaesthesia. Preoperative medication included morphine and lorazepam. Two iv catheters, a radial artery catheter, and a left internal jugular catheter were inserted under local anaesthesia. A thermodilution pulmonary artery catheter was used to measure cardiac output and right and left side cardiac pressures. Ketamine or sufentanil was administered to consecutive patients in an alternating fashion. No subject was excluded or choice of induction drug altered because of the patient's physical. condition. Nine patients were anaesthetized with ketamine, 1.5 mg-kg -~ iv producing loss of responsiveness. The remaining eight patients were anaesthetized with sufentanil, 3.59 ttg-kg-~ mean dose with a range of 2.75 to 4.85. The sufentanil was infused using a diluted 5 p,g. ml -~ concentration at the rate of 100 ttg" min -~ until loss of responsiveness. Muscle relaxation was achieved using vecuronium, 0.11 to 0.30 mg-kg-I. The lungs were ventilated manually with oxygen prior to direct laryngoscopy and intubation. Haemodynamic measurements and blood samples were obtained preinduction (control), preintubation, and at two, five, and ten minutes after intubation. Heart rate (HR), mean arterial pressure Mean ---SEM, NS -not significant.
(MAP), mean pulmonary artery pressure (MPAP), mean pulmonary capillary wedge pressure (PCWP), right atrial pressure (RAP), and cardiac output in triplicate were measured at each time period. Arterial blood samples were analyzed for ANP, norepinephrine (NE) and epinephrine (EPI). Plasma catecholamines were absorbed onto alumina, eluted with acetic acid, and measured by highperformance liquid chromatography with electrochemical detection as described by Glisson. ~2 Normal plasma NE and EP! values in our laboratory are 150-300 and 50-150 pg. ml -t, respectively. The assay sensitivity is 40 pg' ml-i plasma with a reproducibility of 7.0%. The ANP was extracted from plasma using C I8 Sep Pak | cartridges. Aliquots were assayed for ANP using the Amersham 1251 ANP radioimmunoassay. Plasma ANP concentrations were determined from a standard curve of known amounts of ANP assayed in parallel with the plasma samples. Normal plasma ANP values in our laboratory are 35-60 pg.ml -t. The assay sensitivity and reproducibility are 12.0 pg. ml-t and I 1.0%, respectively. Chemistry values have been corrected to reflect 100% extraction recovery.
The data are presented as the mean -SEM. Statistical analysis of the data included repeated measures ANOVA and, when indicated, post hoc testing using paired and unpaired t tests with Bonferroni's adjustment for multiple comparisons. The ANP, NE and EPI results were analyzed using the Kruskal-Wallis and Mann-Whitney tests. A probability of 0.05 was accepted to indicate a significant difference between the groups.
Results
Demographic data for the ketamine and sufentanil groups are shown in Table 1 . Cardiovascular responses (Table I1) show that patients in the ketamine group had increases in RAP and PCWP to about twice their control values with HR, MAP and MPAP 20-50% greater than control (P < 0.05). Cardiac index was decreased following ketamine to a level 19% below the preinduction value (P < 0.05). Among the derived haemodynamic variables an increase was observed in systemic vascular resistance, while the stroke volume index decreased. Plasma NE concentra- tions in the ketamine group more than doubled (P < 0.5). However, the increases in EPI were not consistent (Figures 1 and 2 ). Plasma concentrations of ANP in the ketamine group were not different from control at any time ( Figure 3) . Patients in the sufentanil group remained haemodynamically stable during the study (Table I1) . Right atrial pressure, PCWP, MAP, MPAP, CI and HR were not different from control at any time. Likewise, plasma NE, EPI and ANP concentrations did not change (Figures I-3) .
There was no difference in the preinduction haemodynamic and chemistry values between the ketamine and sufentanil groups. However, the preinduction norepinephrine, EPI and ANP concentrations were markedly higher than normal values. 8"9 Plasma ANP values in the treatment groups were not different. After induction of anaesthesia, values for PCWP, CI, MAP, MPAP, SVR and NE were different in the ketamine and sufentanil groups.
Discussion
The release of ANP from cardiac atrial myocytes initiates diuretic and natriuretic responses to maintain appropriate fluid and electrolyte balance in the body. in the normal subject distension and stretch of the fight atrial myocytes is the stimulus for the secretion of ANP which is synthesized and stored in granules within the myocytes. 7 Conversely, ANP release in patients with CHF has been shown to correlate more closely with pressure change in the left atrium than in the right. Further ANP release per mmHg rise in atrial pressure is less than normal in CHF patients, while patients with cardiomyopathy or valve disease release even less ANP per mmHg pressure increase. 9 The present study demonstrated a lack of ANP release despite doubling of atrial and pulmonary capillary wedge pressures in patients with end-stage cardiomyopathy. This observation is consistent with the above reports. It would appear that a decline in atrial ANP response to pressure increase parallels a decline in cardiac function. In the study by Matsubara et al. 9 cardiomyopathy patients were not at end-stage failure requiring heart transplantation as did the patients in this study, and ANP release to increased atrial pressure, although reduced, was still present. The reasons given for the decline in ANP responsiveness were a structural change with extensive replacement of atrial muscle by fibrous tissue, and a diminished elasticity to atrial wall stretch. Depleted ANP stores resulting from the structural alterations was suggested as the cause of the decreased ANP release. Similar findings in animals with experimentally induced cardio- myopathies showing ANP in atrial tissue to be depleted has been reported, m''~ The elevated preinduction concentration of plasma ANP found in this study was not different from published resting ANP levels in cardiac and transplanted heart patients of 12 to 60 pg'mi-~, t3-t8 Congestive heart failure patients, on the other hand, have highly elevated resting ANP levels often in the range of 300 pg. ml-t.a.tg.2o It has been suggested that the increase in circulating ANP initially functions as a compensatory natriuretic response to increased body fluid volume, 6'2t-23 but that over time the responsiveness of the renal receptors to ANP is diminished. ,4.,5 It would appear that a positive feedback is established until such time" as the atria under chronic elevated pressure undergo structural alteration leading to a reduction in ANP secretion 9 as was observed in this study.
Patients in the present study had end-stage heart failure with an average ejection fraction of 0.16 _+ 0.02. In the design of the study the authors took advantage of the acute increase in RAP and PCWP that occurs following ketamine as the stimulus to study A N P release prior to orthotopic heart transplantation. However, the increased atrial pressure that occurs following ketamine may not be equivalent to the increased pressure and stretch that occurs secondary to volume loading, a procedure which we were unable to carry out in these transplant patients. Volume loading is associated with atrial distension, pressure increase and stretch of the myocyte and leads to ANP release. 7,'3 Ketamine on the other hand increases atrial pressure presumably by decreasing cardiac compliance and increasing afterioad. Some atrial distension is to be expected due to redistribution of fluid volume to the central compartment, but not to the extent of volume loading. The extent of stretch of the myocytes necessary to evoke ANP release is not known. Bates et al. 2t reported that right atrial pressures greater than 8 mmHg or pulmonary capillary wedge pressures greater than 16 mmHg were necessary to induce elevated ANP levels in CHF patients. Right atrial and PCWP pressures in the ketamine group were 14 and 37 mmHg, respectively. Release of ANP has been reported in man following elevation of the legs, 13 ventriculoatrial pacing, 2 and in experimental animals following mitral valve obstruc-tion. 7 Further, infusion of the vasoconstrictor, vasopressin, into rats was reported to increase right atrial pressure with a significant release of ANP. 23 These findings suggest that increased atrial pressure secondary to ketamine is sufficient stimulus for ANP release from atrial myocytes.
A second concern is whether ketamine might block the release of ANP. A review of the literature did not offer evidence of ketamine's effect on ANP in man. However, the effect of ketamine and other anaesthetics on ANP in rats has been studied. 24 Ether, morphine, chloral hydrate and ketamine each more than doubled plasma ANP levels in the rat with morphine causing the greatest increase. Only sodium pentobarbital and urethane were found to decrease plasma ANP levels. Although rat is not man, the response to numerous drugs in rat and man is similar. In light of these findings, it would seem unlikely that the diminished ANP response obtained from the cardiomyopathy patients was due to their receiving ketamine.
Patients with CHF typically show an increase in ANP release with acute volume loading and increased atrial pressure. 14,15.19 The difference between these reports and the present findings probably reflects the stage of heart failure in the patients studied. Ejection fractions, when reported, were above 37% compared with 16% in this study. 19 Also, the finding of elevated resting plasma catecholamine concentrations (preinduction) in our study is consistent with previous studies of cardiomyopathy patients 22'2s and of patients with CHF. 26'27 Norepinephrine is reported to be a stimulus for ANP release in mitral valve and dilated cardiomyopathy patients, but not in normal subjects. 9 That ANP release was not increased in spite of markedly elevated plasma norepinephrine levels in these transplant patients provides further evidence of their diminished atrial ANP responsiveness.
Based upon these findings and the results of others, the authors propose that a diminution of atrial ANP responsiveness occurs as cardiac failure progresses toward the terminal stage. In the earlier stages of heart failure circulating ANP concentrations and atrial release are increased in conjunction with diminished renal responsiveness to ANP over time. In the case of refractory cardiomyopathies the inability of the atrial myocytes to release ANP in response to acutely increased atrial pressure could reflect an exhaustion of the atrial ANP mechanism following an extended period, often years, of heightened release by the myocytes. In refractory cardiomyopathy patients ANP appears to exert little influence on the control of fluid volume or blood pressure. in summary, the findings of this study demonstrate that end-stage cardiomyopathy patients do not exhibit increased ANP release in response to acutely increased atrial pressure despite the presence of elevated circulating ANP levels characteristic of heart failure. The dysfunction of the atrial ANP release mechanism appears to parallel the dysfunction of the heart.
